- About us
Malaria research in drug development, deployment and resistance
The ACT Consortium: a research consortium to optimize the delivery of effective anti-malarial treatment.
The ACT Consortium is an international research collaboration aiming to maximize the public health impact of artemisinin-based combination therapy (ACT) through high quality, policy-driven, multidisciplinary operational research.
Active in 10 countries and with partners world-wide, we use a variety of study designs including complex evaluations to address questions about:
- How to improve access to good-quality ACTs for those who most need them;
- How to target ACTs to patients with malaria, through the deployment of Rapid Diagnostic Tests;
- Drug quality, by assessing the prevalence of sub-standard and counterfeit artemisinin drugs;
- The safety of ACTs under operational conditions, especially in high risk groups and when used in combination with other drugs.
Answering these key questions will help give policy makers and programme managers the evidence they need to ensure effective alaria control programmes can be implemented.